Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
A new online resource is now available to help people recognize and find high quality care for alcohol use disorder, which affects more than 15 million adults in the United States. The Alcohol Treatment Navigator, designed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health, is a comprehensive, yet easy-to-use tool to help individuals and their loved ones navigate the often-complicated process of choosing treatment for alcohol problems. With many treatment options available, the navigator makes the search easier by telling them what they need to know - and what they need to do – to find appropriate, quality care.
“We developed this tool to help address the alcohol ‘treatment gap,’” said NIAAA Director George F. Koob, Ph.D. “In any given year, less than 10 percent of individuals diagnosed with alcohol use disorder receive treatment, and many of them do not receive the type of care that best fits their needs. A big reason for that, we believe, is that people with alcohol use disorder often don’t know where to turn for help. The Alcohol Treatment Navigator offers a comprehensive strategy to help people search for professionally-led, evidence-based alcohol treatment, which should improve their chances for success.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8179051-niaaa-alcohol-treatment-navigator/
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8121952-st-jude-childrens-childhood-solid-tumor-network/
Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CCSS), a National Cancer Institute-funded resource for late-effects research, led by investigators at St. Jude Children’s Research Hospital.
“This is the first comprehensive study to demonstrate how changes in treatments over time have impacted the occurrence of late effects experienced by childhood cancer survivors,” said Todd Gibson, Ph.D., assistant member of the Department of Epidemiology and Cancer Control at St. Jude. “We found the 15-year cumulative incidence of people reporting at least one severe health condition decreased from 12.7 percent among childhood cancer survivors diagnosed in the 1970s to 10.1 percent for those diagnosed in the 1980s to 8.8 percent in the 1990s–a statistically significant decline.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7924756-st-jude-childhood-cancer-survivorship-asco-2017/
Don’t trust us, trust Science: Abbott is among the best science-based companies to work for in the world.
For the 13th consecutive year, the journal Science today recognized Abbott on its Top Employers list, evaluated on 23 characteristics including financial strength, easy adaptation to change and a having a research-driven environment.
”Abbott is unique in that we’ve been adding to our reservoir of scientific knowledge for 128 years,“ said John Frels, Ph.D., chair of Abbott’s Scientific Governing Board, which oversees the company’s senior scientific career track. ”We strive to bring in the best and brightest scientists and engineers to work on some of the biggest problems in healthcare today. This helps us to create new, breakthrough innovations that change people’s lives.“
To view the multimedia release go to:
http://www.multivu.com/players/English/7962251-science-names-abbott-2016-top-employer/
Soy consumption is up 14 percent since 2011,26 yet confusion lingers over soy’s role in everything from human health to food production. To clear up misperceptions, the United Soybean Board (USB) busts five common soy myths with science-backed facts on SoyConnection.com/soy-wisdom.
1) Eating soy does not increase breast cancer risk.
Clinical studies show soy isoflavone exposure does not adversely affect breast tissue as assessed by markers of breast cancer risk, such as breast cell proliferation.1–7 The American Institute for Cancer Research and the American Cancer Society say that women who have been diagnosed with breast cancer can safely consume soyfoods. In fact, the World Cancer Research Fund International has identified a link between soy consumption and an improved survival of breast cancer patients.8-9
“Not only does evidence indicate soyfoods may benefit women with breast cancer, but consuming soy when young helps prevent the onset of this disease later in life27-30,” stated Mark Messina, Ph.D., who has dedicated the past 30 years to understanding the health effects of soyfoods.
To view the multimedia release go to:
http://www.multivu.com/players/English/7877951-united-soybean-board-top-soy-myths/
When you’re a brilliant mathematician like the Baltimore Ravens’ John Urschel, a football playbook is only so challenging. So the 6-foot-3, 305-pound offensive lineman looks for mathematics in everyday life for mental stimulation, and he’s asking you to do the same. Get in the game by snapping photos of how and where you use math at school, at home, on the practice field — anywhere and everywhere – for a chance to win a $500 Amazon gift card and a video conference for your class with the professional athlete.
Kicking off August 19, in coordination with World Photo Day (#WorldPhotoDay), and running through September 17, you can show John Urschel how you use math for the win in everyday life on Twitter or Instagram using the hashtags #MathFTW and #TIContest to be entered to win. And, get creative! The gifted mathematician is seeing a lot of math these days as he pursues his Ph.D. in Applied Mathematics at Massachusetts Institute of Technology (MIT). Urschel, who holds a 4.0 Grade Point Average, is all the proof students need to see they can be good at academics while pursuing other passions – from athletics to the arts.
To view the multimedia release go to:
http://www.multivu.com/players/English/7746253-texas-instruments-math-for-the-win-contest/
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here.
“Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
Society for Science & the Public (Society) today announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is the new title sponsor of the Science Talent Search. Selected through a competitive process that garnered interest from the nation’s leading companies and philanthropists, Regeneron will become only the third sponsor in 75 years of the nation’s oldest and most prestigious high school science competition.
The new sponsorship will be celebrated at a special event today at the American Museum of Natural History, which is known for its extensive science education program. The event will be hosted by astrophysicist Neil deGrasse Tyson, Ph.D., Frederick P. Rose director of the Hayden Planetarium at the American Museum of Natural History, and can be viewed via webcast at 9:00 a.m. EDT at http://edge.media-server.com/m/go/sciencetalentsearch.
Regeneron is committing $100 million to support the Science Talent Search and other Society programs through 2026 and will assume title sponsorship of the competition effectively immediately. As part of its commitment, Regeneron is nearly doubling the overall award distribution to $3.1 million annually, increasing the top award to $250,000, and doubling the awards for the top 300 young scientists and their schools to $2,000 each. During its history, the Science Talent Search has provided more than $25 million in awards to over 8,500 students and schools.
To view the multimedia release go to:
http://www.multivu.com/players/English/7846351-regeneron-science-talent-search/
Eli Lilly and Company (NYSE: LLY) will commemorate its 140th anniversary today with activities at Lilly locations worldwide, including a ceremony to unveil a statue dedicated to founder Colonel Eli Lilly at global headquarters in Indianapolis.
Over 14 decades, the organization has contributed more than 100 medicines and significant medical advances, such as the first commercially available insulin, manufacturing and global distribution of the Salk polio vaccine and mental health breakthroughs such as anti-depressant Prozac® (fluoxetine). Today Lilly continues to progress its most robust pipeline in history with dozens of potential new medicines in mid- to late-stage development for cancer, diabetes, autoimmune disease, pain and Alzheimer’s disease.
“As Lilly celebrates 140 years, we’re keeping the vision of our founder alive – from our dedication in the lab to our impact in the community,” said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer, who began his career at Lilly as a chemist in 1979. “Colonel Eli Lilly started this company to put science to work fighting disease and encouraged his successors to ‘take what you find here and make it better and better.’ That vision pushes us daily to honor Colonel Lilly’s legacy and continue in our quest to discover new medicines to help make life better.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7809951-eli-lilly-and-company-140th-anniversary/
Regional winners of the Rotten Sneaker Contest® gathered at Ripley’s Believe It Or Not! Times Square for the 2016 national competition. Six contestants from across the country, ages seven to thirteen, went head-to head in New York City today to show off their foul smelling sneakers for a chance to win the national title. But only one pair of sneakers could be crowned the winner and they belonged to 12 year old, Mason Young-Hiss, from Berthoud, CO.
The Odor-Eaters Rotten Sneaker Contest is the ultimate test that shows how offensive kids’ sneakers can get when they are playing outdoors, splashing through puddles, slogging through mud and more. The contest has a long history (over 40 years) and kids from across the country look forward to this annual event in their hometown. Participants take pride in mucking up their shoes to stand out from their competitors to ultimately win over the judges. Sneakers are judged on the interior and exterior conditions of the shoe, and most importantly odor, by a professional panel that includes NASA “Master Sniffer” George Aldrich, Chemical Specialist for NASA space missions, and Rachel Herz, Ph.D., an expert and author on the psychology of smell. Additionally, Brittany Every, Marketing Manager of Ripley’s Believe Or Not! Times Square joined the expert judges this year. Brittany is accustomed to seeing the unexpected and unusual at Ripley’s so she was up for the task.
To view the multimedia release go to:
http://www.multivu.com/players/English/7720051-odor-eaters-rotten-sneaker-contest/
